Sugi Predict

Sugi Predict / Targets / EPHB3

EPHB3

Ephrin type-B receptor 3 · P54753 · EPHB3 on Sugi Atlas →

14,357 patent compounds predicted against EPHB3, 9,357 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL405792 SCHEMBL405792 0.52 11/20
SCHEMBL402297 SCHEMBL402297 0.47 7/20
SCHEMBL1044120 SCHEMBL1044120 0.58 6/20
SCHEMBL974151 SCHEMBL974151 0.47 6/20
SCHEMBL416200 SCHEMBL416200 0.56 5/20
SCHEMBL403229 SCHEMBL403229 0.48 4/20
SCHEMBL971566 SCHEMBL971566 0.47 4/20
SCHEMBL403981 SCHEMBL403981 0.44 4/20
SCHEMBL376493 SCHEMBL376493 0.39 4/20
SCHEMBL589689 SCHEMBL589689 0.81 3/20
SCHEMBL588806 SCHEMBL588806 0.78 3/20
SCHEMBL357398 SCHEMBL357398 0.59 3/20
SCHEMBL405801 SCHEMBL405801 0.46 3/20
SCHEMBL406767 SCHEMBL406767 0.42 3/20
Dasatinib Anhydrous Dasatinib Anhydrous (SCHEMBL8226) 1.00 2/20
Tae-684 Tae-684 (SCHEMBL282775) 1.00 2/20
Dasatinib Anhydrous Dasatinib Anhydrous (SCHEMBL290515) 1.00 2/20
SCHEMBL1147156 SCHEMBL1147156 0.84 2/20
SCHEMBL1147171 SCHEMBL1147171 0.84 2/20
SCHEMBL1146489 SCHEMBL1146489 0.81 2/20

Clinical trials — most relevant to EPHB3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Improving Outcomes in Neonatal Abstinence Syndrome PHASE3COMPLETED
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors PHASE1/PHASE2COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） PHASE2RECRUITING
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC PHASE1/PHASE2UNKNOWN
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) PHASE2ACTIVE_NOT_RECRUITING
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas PHASE1COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Family Blood Pressure Program - HyperGEN nanCOMPLETED
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury nanUNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Family Blood Pressure Program - GENOA nanCOMPLETED
Family Blood Pressure Program - SAPPHIRe Network nanCOMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Genetics of Arteriovenous Malformations nanUNKNOWN
The Locus Coeruleus, Norepinephrine and Cognitive Aging nanACTIVE_NOT_RECRUITING
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy. nanUNKNOWN
The Role of Gene Changes in Brain Tumor Formation and Growth nanCOMPLETED
HYPGENE-Genetics Fitness Obesity & Risk of Hypertension nanCOMPLETED
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children nanCOMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Risk Burden of Lipoprotein Metabolic Gene Haplotypes nanCOMPLETED
Identifying Genes That May Increase the Risk for Heart Disease in African Americans nanCOMPLETED
Aneurysm Genetic Risk in Patients With QIB Changes nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EPHB3 binder may also engage these)

ProteinNameSimilarity
P54754 — 1.000 P54754 →
Q91735 — 1.000 Q91735 →
Q07497 — 0.999 Q07497 →
Q07498 — 0.999 Q07498 →
O09127 — 0.999 O09127 →
Q03145 — 0.999 Q03145 →
Q1KL86 — 0.999 Q1KL86 →
Q60629 — 0.999 Q60629 →
P54757 — 0.998 P54757 →
P54755 — 0.998 P54755 →
EPHA5 Ephrin type-A receptor 5 0.998 landscape →
Q90344 — 0.997 Q90344 →
EPHB4 Ephrin type-B receptor 4 0.997 landscape →
O73878 — 0.996 O73878 →
Q8CBF3 — 0.996 Q8CBF3 →
O13146 — 0.996 O13146 →
EPHA2 Ephrin type-A receptor 2 0.996 landscape →
EPHA8 Ephrin type-A receptor 8 0.996 landscape →
O42422 — 0.995 O42422 →
O73875 — 0.995 O73875 →
P09759 — 0.995 P09759 →
EPHA6 Ephrin type-A receptor 6 0.995 landscape →
Q91571 — 0.995 Q91571 →
P54761 — 0.993 P54761 →
EPHA3 Ephrin type-A receptor 3 0.993 landscape →
Q91736 — 0.993 Q91736 →
EPHB1 Ephrin type-B receptor 1 0.993 landscape →
Q91694 — 0.993 Q91694 →
P54759 — 0.993 P54759 →
P54763 — 0.993 P54763 →